Portal de Periódicos da CAPES

Gabaergic Drugs and Alzheimer’s Disease

2011; Future Science Ltd; Volume: 3; Issue: 2 Linguagem: Inglês

10.4155/fmc.10.291

1756-8927

Agenor Limón, Jorge Mauricio Reyes‐Ruiz, Ricardo Miledi,

Neuroscience and Neuropharmacology Research

Future Medicinal ChemistryVol. 3, No. 2 CommentaryGABAergic drugs and Alzheimer's diseaseAgenor Limon, Jorge Mauricio Reyes-Ruiz & Ricardo MilediAgenor LimonLaboratory of Cellular & Molecular Neurobiology, Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA 92697-4550, USA, Jorge Mauricio Reyes-RuizLaboratory of Cellular & Molecular Neurobiology, Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA 92697-4550, USA & Ricardo Miledi† Author for correspondencePublished Online:11 Feb 2011https://doi.org/10.4155/fmc.10.291AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleBibliography1 Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with Alzheimer's disease (AD) after Aβ42 immunization. Neurology61(1),46–54 (2003).Crossref, Medline, CAS, Google Scholar2 Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov.9(10),749–751 (2010).Crossref, Medline, CAS, Google Scholar3 LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci.8(7),499–509 (2007).Crossref, Medline, CAS, Google Scholar4 Palop JJ, Chin J, Roberson ED et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron55(5),697–711 (2007).Crossref, Medline, CAS, Google Scholar5 Scarmeas N, Honig LS, Choi H et al. Seizures in Alzheimer disease: who, when, and how common? Arch. Neurol.66(8),992–997 (2009).Medline, Google Scholar6 Ittner LM, Ke YD, Delerue F et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell142(3),387–397 (2010).Crossref, Medline, CAS, Google Scholar7 Parodi J, Sepúlveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG. β-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J. Biol. Chem.285(4),2506–2514 (2010).Crossref, Medline, CAS, Google Scholar8 Querfurth HW, LaFerla FM. Alzheimer's disease. N. Engl. J. Med.362(4),329–344 (2010).Crossref, Medline, CAS, Google Scholar9 Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med.148(5),379–397 (2008).Crossref, Medline, Google Scholar10 Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J. Neurochem.103(4),1285–1292 (2007).Crossref, Medline, CAS, Google Scholar11 Lawrence JJ. Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci.31(7),317–327 (2008).Crossref, Medline, CAS, Google Scholar12 Ellender TJ, Paulsen O. The many tunes of perisomatic targeting interneurons in the hippocampal network. Front Cell Neurosci.30(4),pii: 26 (2010).Google Scholar13 Somogyi P, Klausberger T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol.562(Pt 1),9–26 (2005).Crossref, Medline, CAS, Google Scholar14 Sernagor E, Chabrol F, Bony G, Cancedda L. GABAergic control of neurite outgrowth and remodeling during development and adult neurogenesis: general rules and differences in diverse systems. Front. Cell Neurosci.4,11 (2010).Crossref, Medline, Google Scholar15 Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev.60(3),243–260 (2008).Crossref, Medline, CAS, Google Scholar16 Marczynski TJ. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain Res. Bull.45(4),341–379 (1998).Crossref, Medline, CAS, Google Scholar17 Dawson GR, Maubach KA, Collinson N et al. An inverse agonist selective for α5 subunit-containing GABAA receptors enhances cognition. J. Pharmacol. Exp. Ther.316(3),1335–1345 (2006).Crossref, Medline, CAS, Google Scholar18 Martin LJ, Bonin RP, Orser BA. The physiological properties and therapeutic potential of α5-GABAA receptors. BioChemSoc Trans.37(Pt 6),1334–1337 (2009).Crossref, Medline, CAS, Google Scholar19 Atack JR. Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA. Pharmacol. Ther.125(1),11–26 (2010).Crossref, Medline, CAS, Google Scholar20 Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci.6(3),215–229 (2005).Crossref, Medline, CAS, Google Scholar21 Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J. Neurosci.28(6),1421–1426 (2008).Crossref, Medline, CAS, Google Scholar22 Lee S, Yoon BE, Berglund K et al. Channel-mediated tonic GABA release from glia. Science330(6005),790–796 (2010).Crossref, Medline, CAS, Google Scholar23 Li G, Bien-Ly N, Andrews-Zwilling Y et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell5(6),634–645 (2009).Crossref, Medline, CAS, Google Scholar24 Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol.172(5),2731–2738 (2004).Crossref, Medline, CAS, Google Scholar25 Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. J. Neurochem.103(3),1237–1257 (2007).Crossref, Medline, CAS, Google Scholar26 Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, DeKosky ST. An immunohistochemical study of GABAA receptor γ subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology29(3),263–269 (2009).Crossref, Medline, Google Scholar27 Limon A, Reyes-Ruiz JM, Vaswani RG, Chamberlin AR, Miledi R. Kaitocephalin antagonism of glutamate receptors expressed in Xenopus oocytes. ACS Chem. Neurosci.1(3),175–181 (2010).Crossref, Medline, CAS, Google Scholar28 Inoue S. In situ Aβ pores in AD brain are cylindrical assembly of Aβ protofilaments. Amyloid15(4),223–233 (2008).Crossref, Medline, CAS, Google Scholar29 Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci.27(11),2866–2875 (2007).Crossref, Medline, CAS, Google Scholar30 Small DH, Maksel D, Kerr ML et al. The β-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor. J. Neurochem.101(6),1527–1538 (2007).Crossref, Medline, CAS, Google Scholar31 Yang X, Askarova S, Lee JC. Membrane biophysics and mechanics in Alzheimer's disease. Mol. Neurobiol.41(2–3),138–148 (2010).Crossref, Medline, CAS, Google Scholar32 Miledi R, Dueñas Z, Martinez-Torres A, Kawas CH, Eusebi F. Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. Proc. Natl Acad. Sci. USA101(6),1760–1763 (2004).Crossref, Medline, CAS, Google Scholar33 Bernareggi A, Dueñas Z, Reyes-Ruiz JM, Ruzzier F, Miledi R. Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc. Natl. Acad. Sci. USA104(8),2956–2960 (2007).Crossref, Medline, CAS, Google Scholar34 Palma E, Torchia G, Limatola C et al. BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes. Proc. Natl Acad. Sci. USA102(5),1667–1672 (2005).Crossref, Medline, CAS, Google Scholar35 Limon A, Reyes-Ruiz JM, Miledi R. Microtransplantation of neurotransmitter receptors from postmortem autistic brains to Xenopus oocytes. Proc. Natl Acad. Sci. USA105(31),10973–10977 (2008).Crossref, Medline, CAS, Google Scholar36 Spitzer NC. A Rosetta stone for analysis of human membrane protein function. Proc. Natl Acad. Sci. USA105(31),10641–10642 (2008).Crossref, Medline, CAS, Google Scholar37 Eusebi F, Palma E, Amici M, Miledi R. Microtransplantation of ligand-gated receptor-channels from fresh or frozen nervous tissue into Xenopus oocytes: a potent tool for expanding functional information. Prog. Neurobiol.88(1),32–40 (2009).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByFunctional impairment of cortical AMPA receptors in schizophreniaSchizophrenia Research, Vol. 16Amyloid-Beta1-42 -Induced Increase in GABAergic Tonic Conductance in Mouse Hippocampal CA1 Pyramidal Cells6 February 2020 | Molecules, Vol. 25, No. 3Electrophysiological evaluation of extracellular spermine and alkaline pH on synaptic human GABAA receptors5 September 2019 | Translational Psychiatry, Vol. 9, No. 1Human brain transcriptome analysis finds region- and subject-specific expression signatures of GABAAR subunits1 May 2019 | Communications Biology, Vol. 2, No. 1Therapeutic Potential of Multifunctional Tacrine AnaloguesCurrent Neuropharmacology, Vol. 17, No. 5Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer's disease10 October 2017 | Molecular Neurodegeneration, Vol. 12, No. 1Direct evidence for GABAergic activity of Withania somnifera on mammalian ionotropic GABAA and GABAρ receptorsJournal of Ethnopharmacology, Vol. 171A review on Alzheimer's disease pathophysiology and its management: an updatePharmacological Reports, Vol. 67, No. 2Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's diseaseNeurobiology of Aging, Vol. 36, No. 2GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease25 June 2014 | Frontiers in Cellular Neuroscience, Vol. 8The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's diseaseNeurobiology of Aging, Vol. 35, No. 6In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's diseaseNeuroscience, Vol. 265Therapeutics of Alzheimer's disease: Past, present and futureNeuropharmacology, Vol. 76Synthesis of novel cognition enhancers with pyrazolo[5,1- c ][1,2,4]benzotriazine core acting at γ-aminobutyric acid type A (GABA A ) receptorBioorganic & Medicinal Chemistry, Vol. 21, No. 8Welcome to 'GABAergic drugs'P Veeraraghavan Ramachandran & Anantha Shekhar11 February 2011 | Future Medicinal Chemistry, Vol. 3, No. 2 Vol. 3, No. 2 Follow us on social media for the latest updates Metrics Downloaded 932 times History Published online 11 February 2011 Published in print February 2011 Information© Future Science LtdFinancial & competing interests disclosureThe authors wish to thank the American Health Assistance Foundation (Grant A2006-054) and the King Abdul Aziz City for Science and Technology (Grant KACST-46749) for their support. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download